Page 24 - Steve Scala News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steve scala. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steve Scala Today - Breaking & Trending Today

U.S. FDA approves Bristol Myers' bowel disease treatment

U.S. FDA approves Bristol Myers' bowel disease treatment
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.

Steve Scala , Bristol Myers Squibb , Bristol Myers , Thomson Reuters Trust Principles , Takeda Pharmaceutical Co , European Medicines Agency , Drug Administration , Thomson Reuters Trust , ஸ்டீவ் ஸ்கால , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , பிரிஸ்டல் மைஸ் , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ் , டாகேடா மருந்து இணை , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ,

GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript

GlaxoSmithKline plc (GSK) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
GlaxoSmithKline plc (NYSE: GSK)
Operator
Good afternoon, ladies and gentlemen. And welcome to the Analyst Call on the GSK First Quarter 2021 Results. I will now hand you over to Iain Mackay, our CFO, who will introduce today s session.SPONSORED:
10 stocks we like better than GlaxoSmithKline
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market. ....

United Kingdom , United States , Graham Parry , David Redfern , Dame Emma Walmsley , Matthew Weston , Andrew Baum , Tim Anderson , Kerry Holford Berenberg , Luke Miels , Brian Mcnamara , Iain Mackay , Hal Barron , Andrew Baum Citigroup , Mark Purcell , Steve Scala Cowen , Kerry Holford , Steve Scala , Simon Mathew , Emma Walmsley , America Merrill Lynch , Keyur Parekh Goldman Sachs , Mark Purcell Morgan Stanley , Peter Welford Jefferies , Keyur Parekh , Simon Matthew Raymond James ,

Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript

Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Eli Lilly and Company (NYSE: LLY)
Popular Searches
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the conference over to our host, Mr. Kevin Hern. Please go ahead.SPONSORED:
10 stocks we like better than Eli Lilly and Company
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ....

United States , White House , District Of Columbia , Mike Mason , Dave Ricks , Andrew Baum , Ilya Yuffa , Eli Lilly , Terence Flynn Goldman Sachs , Danielm Skovronsky , Aarti Shah , Louise Chen Cantor Fitzgerald , Terence Flynn , Steve Scala Cowen , Kerry Holford , Geoff Meacham , Carter Gould Barclays , Seamus Fernandez Guggenheim , Myles Oneill , Gregg Gilbert , Louise Chen , Edgardo Hernandez , Diogo Rau , Tim Anderson , Michaelb Mason , Kerry Holford Berenberg ,

GSK stops studies testing closely watched cancer immunotherapy

Dive Brief:
GlaxoSmithKline will stop enrolling cancer patients into two mid-stage studies testing a closely watched cancer immunotherapy alongside Merck & Co. s Keytruda, marking another setback for the British drugmaker s ambitions in oncology research.
The decision followed a recommendation from an independent monitoring committee that oversees one of the trials. In a Wednesday statement, GSK said it will evaluate the totality of the data to determine the impact on its broader development plans for the drug, called feladilimab.
Feladilimab is a top drug prospect for GSK, one of a class of experimental cancer medicines known as ICOS receptor agonists. But their potential may now be in question after GSK s decision and the failure of a study testing a similar drug from Jounce Therapeutics last fall. ....

United Kingdom , Steve Scala , Hal Barron , Andrew Witty , Merck Kga , Merck Kgaa , Drug Administration , Merck Co , Bristol Myers Squibb , Dive Brief , Jounce Therapeutics , ஒன்றுபட்டது கிஂக்டம் , ஸ்டீவ் ஸ்கால , ஹால் பரோன் , ஆண்ட்ரூ அறிவாற்ற்ல் , மெர்க் க்க , மெர்க் இணை , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , டைவ் சுருக்கமான ,

Repros Therapeutics (RPRX) Q4 2020 Earnings Call Transcript

Repros Therapeutics (RPRX) Q4 2020 Earnings Call Transcript
Motley Fool Transcribing
© The Motley Fool
Logo of jester cap with thought bubble.
Repros Therapeutics (NASDAQ: RPRX)
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma fourth-quarter 2020 financial results conference call. I would now like to turn the call over to George Grofik, senior vice president, head of investor relations and communications. Please go ahead, sir.
George Grofik
Senior Vice President, Head of Investor Relations and Communications.
Thank you, operator, and good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma s fourth-quarter results. You can find the slides of this call on the investors page of our website at royaltypharma.com. Moving to Slide 3. ....

David Risinger , Terence Flynn Goldman Sachs , Jim Reddoch , Terry Coyne , Pablo Legorreta , Terence Flynn , Geoff Meacham , Steve Scala Cowen , Steve Scala , America Merrill Lynch , Mike Difiore , George Grofik , Gregg Gilbert , Mike Difiore Evercore , David Risinger Morgan Stanley , Chris Schott , Gregg Gilbert Truist , Marshall Urist , Morgan Stanley , Head Of Research , Goldman Sachs , Geoff Meacham Bank , Company Analyst , Repros Therapeutics , Motley Fool Repros Therapeutics , Call Transcript ,